Chengdu Olymvax Overview
- Status
-
Public
- Employees
-
451
- Stock Symbol
-
688319
- Investments
-
1
- Share Price
-
$4.15
- (As of Thursday Closing)
Chengdu Olymvax General Information
Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
Contact Information
Website
www.olymvax.comCorporate Office
- 99 Tianxin Road
- High-tech Zone
- Chengdu, Sichuan 611731
- China
Corporate Office
- 99 Tianxin Road
- High-tech Zone
- Chengdu, Sichuan 611731
- China
Chengdu Olymvax Stock Performance
As of 12-Nov-2026, Chengdu Olymvax’s stock price is $4.15. Its current market cap is $1.68B with 405M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.15 | $4.23 | $3.00 - $6.61 | $1.68B | 405M | 5.99M | -$0.01 |
Chengdu Olymvax Financials Summary
As of 30-Sep-2026, Chengdu Olymvax has a trailing 12-month revenue of $116M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,928,709 | 1,498,188 | 605,767 | 881,568 |
| Revenue | 115,510 | 97,918 | 82,066 | 70,124 |
| EBITDA | 6,791 | 11,805 | 8,996 | 7,215 |
| Net Income | (4,646) | 3,095 | 2,893 | 2,481 |
| Total Assets | 316,612 | 289,146 | 247,537 | 227,493 |
| Total Debt | 75,916 | 61,891 | 49,560 | 33,519 |
Chengdu Olymvax Patents
Chengdu Olymvax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021128948-A1 | Anti-mhin2 protein antibody, and use thereof and kit containing same | Inactive | 26-Dec-2019 | ||
| WO-2021128947-A1 | Anti-mntc protein antibody, use thereof and kit containing same | Inactive | 26-Dec-2019 | ||
| WO-2021128949-A1 | Anti-mseb protein antibody, application thereof and kit containing same | Inactive | 26-Dec-2019 | ||
| WO-2021128946-A1 | Anti-spa5 protein monoclonal antibody, use thereof and kit containing same | Inactive | 26-Dec-2019 | ||
| US-20220267419-A1 | Human immunoglobulin against methicillin-resistant staphylococcus aureus, preparation method therefor, and use thereof | Inactive | 28-Jun-2019 | A61P31/04 |
Chengdu Olymvax Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Chengdu Olymvax Investments (1)
Chengdu Olymvax’s most recent deal was a Secondary Transaction - Private with XinNuoMing Bio for . The deal was made on 17-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| XinNuoMing Bio | 17-Oct-2025 | Secondary Transaction - Private | Drug Delivery |
Chengdu Olymvax ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Chengdu Olymvax FAQs
-
Where is Chengdu Olymvax headquartered?
Chengdu Olymvax is headquartered in Chengdu, China.
-
What is the size of Chengdu Olymvax?
Chengdu Olymvax has 451 total employees.
-
What industry is Chengdu Olymvax in?
Chengdu Olymvax’s primary industry is Biotechnology.
-
Is Chengdu Olymvax a private or public company?
Chengdu Olymvax is a Public company.
-
What is Chengdu Olymvax’s stock symbol?
The ticker symbol for Chengdu Olymvax is 688319.
-
What is the current stock price of Chengdu Olymvax?
As of 12-Nov-2026 the stock price of Chengdu Olymvax is $4.15.
-
What is the current market cap of Chengdu Olymvax?
The current market capitalization of Chengdu Olymvax is $1.68B.
-
What is Chengdu Olymvax’s current revenue?
The trailing twelve month revenue for Chengdu Olymvax is $116M.
-
What is Chengdu Olymvax’s annual earnings per share (EPS)?
Chengdu Olymvax’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
